Last reviewed · How we verify
New formulation of CAB LA — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
New formulation of CAB LA (New formulation of CAB LA) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| New formulation of CAB LA TARGET | New formulation of CAB LA | ViiV Healthcare | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- New formulation of CAB LA CI watch — RSS
- New formulation of CAB LA CI watch — Atom
- New formulation of CAB LA CI watch — JSON
- New formulation of CAB LA alone — RSS
Cite this brief
Drug Landscape (2026). New formulation of CAB LA — Competitive Intelligence Brief. https://druglandscape.com/ci/new-formulation-of-cab-la. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab